Powered By Bing

Pan Lab: Publications

 

2020

  • Rongji Mu, Guoying Xu, and Haitao Pan*. “A nonparametric two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials”. Submitted. *Corresponding author

  • Rongji Mu, Guoying Xu, and Haitao Pan*. “An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials”. Submitted. *Corresponding author

  • Haitao Pan, Cheng, and Ying Yuan. “Bayesian adaptive linearization method (BALM) for phase I drug combination trials with dimension reduction.” Pharmaceutical Statistics (2020) DOI:10.1002/pst.2013

  • Haitao Pan, Ruitao Lin, Yanhong Zhou, and Ying Yuan. “Statistical properties of the Keyboard design with extension to drug-combination trials.” Contemporary Clinical Trials, 2020. DOI:10.1016/j.cct.2020.105972

2019

  • Fangrong Yan, Haitao Pan, Suyu Liu, and Ying Yuan. “An R package for designing single-agent and drug-combination dose-finding trials using Bayesian optimal interval designs.” Journal of Statistical Software, 2019. to appear.

2018

  • Haitao Pan, Suyu Liu, Ying Yuan, and Danmin Miao. “Sample size determination for mediation analysis of longitudinal data.” BMC Medical Research Methodology, 2018. DOI 10.1186/s12874-018-0473-2.

  • Heng, Z., Murray, T., Haitao Pan, and Yuan Y. “Comparative review of toxicity probability interval designs for phase I clinical trials.”  Statistics in Medicine, 2018, 37(14), 2208-2222.

  • Wu K, Haitao Pan*, Li C, Zhao Q, Wang L, and Xia J. An evaluation roadmap for critical quality attributes from tier 1 in analytical similarity assessment. PLoS One. December 2018 *Co-First Author.

  • Kejian W, Qingbo Z, Chanjun L, Ling W, Chen L, Haitao Pan*, and Jielai X*. “Some statistical considerations in analytical similarity assessment of biosimilar studies.” Chinese Journal of Health Statistics 35(3):344-348, 2018. *Corresponding author.

Before 2017

  • Haitao Pan, Ying Yuan, and Jielai Xia. “A calibrated power prior approach to borrow information from historical data with application to biosimilar clinical trials.” Journal of the Royal Statistical Society. Series C, 2017. DOI: 10.1111/rssc.12204.

  • Yiyi Chu, Haitao Pan, and Ying Yuan. “Adaptive dose modification for phase I clinical trials.” Statistics in Medicine, 2016. DOI: 10.1002/sim.6933.

  • Haitao Pan and Ying Yuan. “A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.” Statistics in Medicine, 2016. DOI: 10.1002/sim.6941.

  • Suyu Liu, Haitao Pan*, Jielai Xia, Qin Huang, and Ying Yuan. "Bridging continual reassessment method for phase I clinical trials in different ethnic populations." Statistics in Medicine, 2015. DOI: 10.1002/sim.6442. *Co-First-Author.

  • Haitao Pan, Chanjuan Li, Ling Wang, Zhiwei Jiang, and Jielai Xia. "A three-stage Bayesian adaptive phase I/II design and simulation studies." Communications in Statistics-Simulation and Computation, 2014. 43(2):254-268.

  • Haitao Pan, Ping Liu, Fang Xie, Jielai Xia, and Yuan Ji. "SEARS: Seamless phase I/II dose escalation/expansion with adaptive randomization scheme." Clinical Trials, 2014.11(1):49-59.

  • Haitao Pan, Cailin Zhu, Feng Zhang, Ying Yuan, Shemin Zhang, Wenhong Zhang, Chanjuan Li, LingWang, and Jielai Xia. "The continual reassessment method for multiple toxicity grades: A Bayesian model selection approach." PLOS ONE, 2014. doi: 10.1371/journal.pone.0098147.

  • Haitao Pan, Yuan Ji, Z. Chen, and Jielai Xia. "The choice of phase I Bayesian adaptive design in China." International Journal of Drug Discovery, 2013, 5(1):185-190.

  • Haitao Pan, Ping Huang, Zuoren Wang, L. Wang, Chanjuan Li, and Jielai Xia. "A novel Bayesian phase I/II seamless design." PLOS ONE, 8(9), 2013, doi:10.1371/journal.pone.0073060.